In contrast, it is highly expressed in most human cancers 7, 8 and its expression is associated with tumour progression and poor clinical outcome.8, 9, 10 Moriai et al11 recently showed that targeting survivin may overcome tamoxifen resistance in breast cancer cells. Here, BIRC5 is linked to breast cancer.